EUCTR2011-006181-41-PL进行中（未招募）1 期
An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg Imatinib
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 258
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.CML-CP patients with CHR but with BCR-ABL level > 10% IS after 3 months of imatinib 400 mg treatment. Imatinib monotherapy should have been started within 6 months of CP-CML diagnosis.
- •2.Men and women with CML-CP Ph+ = age 18
- •3.Currently tolerating imatinib 400 mg QD
- •4.ECOG performance status = 0 – 2
- •5.Patient willing and able to give informed consent
- •6.Life expectancy >6 months
- •7.Adequate renal function defined as serum creatinine = 3 times the institutional ULN.
- •8.Adequate hepatic function defined as: total bilirubin = 2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 times the institutional upper limit of normal (ULN).
- •9.Serum Na, K, Mg, and total serum Ca or ionized Ca levels must be greater than or equal to the institutional lower limit of normal. Subjects with low K, Mg levels, total serum Ca and/or ionized Ca must be replete to allow for protocol entry.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 129
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 129
排除标准
- •1.Patients who are pregnant or breastfeeding or likely to become pregnant.
- •2.Men whose partner is unwilling or unable to avoid pregnancy
- •3.Prior or concurrent malignancy, except for the following:
- •a.Curatively treated basal cell or squamous cell skin cancer
- •b.Cervical carcinoma in situ
- •c.Adequately treated Stage I or II cancer from which the subject is currently in complete remission
- •d.Any other cancer from which the subject has been disease free for 3 years
- •4.Documented T315I mutation (if already available – not required for screening)
- •5.Medical History and concurrent medical conditions, including:
- •a.A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
- •b.Uncontrolled or significant cardiovascular disease, including any of the following:
- •i.Congestive cardiac failure (NYHA >2) within 3 months
- •ii.Diagnosed or suspected congenital long QT syndrome
- •iii.Any history of clinically significant ventricular arrhythmias
- •iv.Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- •v.Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)
- •vi.Uncontrolled angina within 3 months
- •vii.Prior myocardial infarction within 6 months
- •viii.Uncontrolled hypertension
- •c.Pulmonary arterial hypertension
- •d.Pleural or pericardial effusions of any grade at randomisation are excluded. Subjects previously diagnosed with pleural/pericardial effusion of any grade resolved at randomisation are allowed.
- •e.History of significant bleeding disorder unrelated to CML, including
- •i.Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)
- •ii.Diagnosed acquire bleeding disorder within on e year (e.g., acquired anti-factor VIII antibodies)
- •f.Prior chemotherapy for peripheral stem cell mobilization. (Prior collection of unmobilized peripheral blood stem cells is permitted).
- •g.Previous diagnosis of accelerated phase or blast crisis
- •h.Subjects with clonal evolution in Ph+ cells observed in = 2 metaphases at baseline bone marrow cytogenetic test, unless the same abnormalities were present at diagnosis. Patients with no evidence of clonal evolution, including those patients whose cytogenetic testing fails or bone marrow aspiration is a dry tap at 3 months, are elegible for the study.
- •i.Subjects with less than Complete Hematologic Response (CHR) after 3 months of imatinib treatment or lost CHR after initial achievement.
- •j.Subjects intolerant to Imatinib 400 mg QD prior to enrolment.
- •6.Prohibited treatments and/or other treatments
- •a.History of TKI exposure within the previous 12 months apart from imatinib
- •b.Subject with any anti-CML other than imatinib (except HU or anagralide)
- •7.Subjects with prior stem cell transplantation and/or high dose chemotherapy for CML
- •8.Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
- •Rescreening is permitted in the event of temporary biochemical abnormalities
研究者
相似试验
进行中（未招募）
不适用
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibChronic Phase Chronic Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-006181-41-ITBristol-Myers Squibb International Corporation180
进行中（未招募）
1 期
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibChronic Phase Chronic Myeloid LeukemiaMedDRA version: 20.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000013009EUCTR2011-006181-41-BEBristol-Myers Squibb International Corporation258
进行中（未招募）
1 期
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibChronic Phase Chronic Myeloid LeukemiaMedDRA version: 20.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-006181-41-CZBristol-Myers Squibb International Corporation258
进行中（未招募）
1 期
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibEUCTR2011-006181-41-ESBristol-Myers Squibb International Corporation260
进行中（未招募）
1 期
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibEUCTR2011-006181-41-ATBristol-Myers Squibb International Corporation258